Literature DB >> 26702708

Comment on "Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions".

Ramachandra Barik1, Lalita Nemani2.   

Abstract

Entities:  

Keywords:  Late lumen loss; Long lesion; Stent; Target lesion failure; Thrombosis; Zotarolimus Eluting Stent

Mesh：

Year:  2015        PMID： 26702708      PMCID： PMC4699973          DOI： 10.1016/j.ihj.2015.08.021

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


× No keyword cloud information.
  8 in total

1.  Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.

Authors:  Takeshi Kimura; Takeshi Morimoto; Yoshihisa Nakagawa; Kazuya Kawai; Shunichi Miyazaki; Toshiya Muramatsu; Nobuo Shiode; Masanobu Namura; Takahito Sone; Shigeru Oshima; Hideo Nishikawa; Yoshikazu Hiasa; Yasuhiko Hayashi; Masakiyo Nobuyoshi; Kazuaki Mitudo
Journal:  Circulation       Date:  2011-12-27       Impact factor: 29.690

2.  The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation.

Authors:  Jon Suh; Duk-Woo Park; Jong-Young Lee; In Hyun Jung; Seung-Whan Lee; Young-Hak Kim; Cheol Whan Lee; Sang-Sig Cheong; Jae-Joong Kim; Seong-Wook Park; Seung-Jung Park
Journal:  JACC Cardiovasc Interv       Date:  2010-04       Impact factor: 11.195

3.  Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.

Authors:  Ron Waksman; Juan Maya; Dominick J Angiolillo; Glenn F Carlson; Renli Teng; Richard J Caplan; Keith C Ferdinand
Journal:  Circ Cardiovasc Interv       Date:  2015-07       Impact factor: 6.546

4.  Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.

Authors:  Gennaro Sardella; Simone Calcagno; Massimo Mancone; Luigi Lucisano; Mauro Pennacchi; Rocco Edoardo Stio; Filippo Placentino; Angelo Di Roma; Erika Cavallo; Raffaele Palmirotta; Fiorella Guadagni; Francesco Fedele
Journal:  Int J Cardiol       Date:  2015-05-15       Impact factor: 4.164

Review 5.  Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.

Authors:  Dániel Aradi; Ajay Kirtane; Laurent Bonello; Paul A Gurbel; Udaya S Tantry; Kurt Huber; Matthias K Freynhofer; Jurrien ten Berg; Paul Janssen; Dominick J Angiolillo; Jolanta M Siller-Matula; Rossella Marcucci; Giuseppe Patti; Fabio Mangiacapra; Marco Valgimigli; Olivier Morel; Tullio Palmerini; Matthew J Price; Thomas Cuisset; Adnan Kastrati; Gregg W Stone; Dirk Sibbing
Journal:  Eur Heart J       Date:  2015-04-20       Impact factor: 29.983

6.  Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions.

Authors:  C G Bahuleyan; V V Krishna Kumar; Shifas Babu
Journal:  Indian Heart J       Date:  2015-05-13

7.  Percutaneous intervention of circumflex chronic total occlusions is associated with worse procedural outcomes: insights from a Multicentre US Registry.

Authors:  Georgios Christopoulos; Dimitri Karmpaliotis; Michael R Wyman; Khaldoon Alaswad; James McCabe; William L Lombardi; J Aaron Grantham; Steven P Marso; Anna P Kotsia; Bavana V Rangan; Santiago A Garcia; Nicholas Lembo; David Kandzari; James Lee; Anna Kalynych; Harold Carlson; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis
Journal:  Can J Cardiol       Date:  2014-07-16       Impact factor: 5.223

8.  Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns.

Authors:  Joseph Shemesh; Alexander Tenenbaum; Enrique Z Fisman; Nira Koren-Morag; Ehud Grossman
Journal:  Cardiovasc Diabetol       Date:  2013-11-05       Impact factor: 9.951
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.